Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.
Julie Rosenthal, MD, MS, discusses the future direction of research into treating age-related macular degeneration.
Stocktwits on MSN
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds
The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular ...
Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...
Newmedica Worcester highlights AMD Awareness Month, urging early detection of age-related macular degeneration—the UK’s leading cause of ...
Newmedica Oxfordshire is highlighting the signs of age-related macular degeneration (AMD) during AMD Awareness Month and is calling for the NHS to publish clearer data on its waiting lists for AMD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results